CYTOMED THERAPEUTICS LTD (GDTC) Stock News

NASDAQ:GDTC - Nasdaq - SGXZ17669631 - Common Stock - Currency: USD

2.02 +0.02 (+0.99%)

After market: 2 -0.02 (-0.99%)

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

GDTC Latest News, Press Relases and Analysis

All

Press Releases

2 days ago - By: CYTOMED THERAPEUTICS LIMITED

Update On Clinical Trial Milestone - CytoMed Therapeutics Achieves Completion of Dose Level 1 of its ANGELICA TRIAL, and Proceeding to Dose Level 2 in Patients with Advanced Solid Tumors or Haematological Malignancies

2 days ago - By: CYTOMED THERAPEUTICS LIMITED

Update On Clinical Trial Milestone - CytoMed Therapeutics Achieves Completion of Dose Level 1 of its ANGELICA TRIAL, and Proceeding to Dose Level 2 in Patients with Advanced Solid Tumors or Haematological Malignancies

3 months ago - By: CYTOMED THERAPEUTICS LIMITED

CytoMed Therapeutics Reports Full Year Ended December 31, 2024 Financial Results and Provides Clinical and Corporate Updates

3 months ago - By: CYTOMED THERAPEUTICS LIMITED

CytoMed Therapeutics Reports Full Year Ended December 31, 2024 Financial Results and Provides Clinical and Corporate Updates

6 months ago - By: CYTOMED THERAPEUTICS LIMITED

CytoMed Therapeutics announces Chairman’s Letter to the Company’s shareholders

6 months ago - By: CYTOMED THERAPEUTICS LIMITED

CytoMed Therapeutics announces Chairman’s Letter to the Company’s shareholders

6 months ago - By: Benzinga - Mentions: NBY SAGE ITCI OCUL ...

12 Health Care Stocks Moving In Monday's Pre-Market Session

7 months ago - By: Benzinga - Mentions: GETY BWNB CDT COGT ...

Why Inari Medical Shares Are Trading Higher By 21%; Here Are 20 Stocks Moving Premarket

7 months ago - By: CYTOMED THERAPEUTICS LIMITED

CytoMed Therapeutics signs Business & Research Collaboration Agreement with India’s SunAct Cancer Institute Private Limited to advance use of allogeneic off-the-shelf Gamma Delta T Cells for treatment of solid cancers in a proposed Phase 2 clinical trial

8 months ago - By: CYTOMED THERAPEUTICS LIMITED

Update on Clinical Milestone - CytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies

8 months ago - By: CYTOMED THERAPEUTICS LIMITED

Update on Clinical Milestone - CytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies

10 months ago - By: CYTOMED THERAPEUTICS LIMITED

CytoMed Therapeutics’ first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding support from the NMRC Clinical Trial Grant

10 months ago - By: CYTOMED THERAPEUTICS LIMITED

CytoMed Therapeutics completes cash acquisition of Cord Blood Banking Licence and Assets expanding CytoMed’s strategy to cord blood-derived biologics through subsidiary, LongevityBank

10 months ago - By: CYTOMED THERAPEUTICS LIMITED

CytoMed Therapeutics’ first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding support from the NMRC Clinical Trial Grant

10 months ago - By: CYTOMED THERAPEUTICS LIMITED

CytoMed Therapeutics completes cash acquisition of Cord Blood Banking Licence and Assets expanding CytoMed’s strategy to cord blood-derived biologics through subsidiary, LongevityBank

10 months ago - By: CYTOMED THERAPEUTICS LIMITED

CytoMed Therapeutics Reports Six Months Ended June 30, 2024 Financial Results and Provides Clinical and Corporate Updates

10 months ago - By: CYTOMED THERAPEUTICS LIMITED

CytoMed Therapeutics Reports Six Months Ended June 30, 2024 Financial Results and Provides Clinical and Corporate Updates

a year ago - By: InvestorPlace - Mentions: SERV SXTP HE PW ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

a year ago - By: CYTOMED THERAPEUTICS LIMITED

CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (γδ) T Cells Technology for Solid and Liquid Cancers

a year ago - By: CYTOMED THERAPEUTICS LIMITED

CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (γδ) T Cells Technology for Solid and Liquid Cancers

a year ago - By: CYTOMED THERAPEUTICS LIMITED

CytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision Therapies

a year ago - By: CYTOMED THERAPEUTICS LIMITED

CytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision Therapies

a year ago - By: CYTOMED THERAPEUTICS LIMITED

CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair

a year ago - By: CYTOMED THERAPEUTICS LIMITED

CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair

1 years ago - By: CYTOMED THERAPEUTICS LIMITED

Malaysian Patent Granted for CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology

1 years ago - By: CYTOMED THERAPEUTICS LIMITED

Malaysian Patent Granted for CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology

2 years ago - By: CytoMed Therapeutics Limited

CytoMed Therapeutics Signs HOA and MOU to Advance Research on Allogeneic Gamma Delta T Cell Technology

2 years ago - By: CytoMed Therapeutics Limited

CytoMed Therapeutics Reports First Half 2023 Financial Report and Provides Corporate Update

2 years ago - By: CytoMed Therapeutics Limited

CytoMed Therapeutics to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference